Skip to main content
. 2012 Mar 8;6:377–383. doi: 10.2147/OPTH.S27731

Figure 3.

Figure 3

(A) Normal responses of the 103 kernals provided by the Veris Corp (The Veris Corporation, McLean, VA) as part of the mfERG package. (B) Widespread loss to all responses in the 40° field of testing in a patient with relatively advanced chloroquine retinal toxicity. (C) Focal reduction in the central macular region with normal responses at the periphery in a patient with typical hydroxychloroquine retinal toxicity.